Edition:
United States

Medicure Inc (MPH.V)

MPH.V on TSX Venture Exchange

0.00CAD
--
Change (% chg)

-- (--)
Prev Close
$0.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$0.00
52-wk Low
$0.00

Latest Key Developments (Source: Significant Developments)

Medicure announces FDA approval for Apicore's generic tetrabenazine
Thursday, 23 Mar 2017 07:30am EDT 

: Medicure announces FDA approval for Apicore's generic tetrabenazine .Medicure Inc - its unit has received final approval from FDA for co's ANDA for tetrabenazine tablets in 12.5 mg and 25 mg strengths.  Full Article

Medicure announces filing of ANDA in collaboration with Apicore
Tuesday, 13 Dec 2016 01:00pm EST 

Medicure Inc : Medicure announces filing of ANDA in collaboration with Apicore . Co and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights .Medicure owns a majority interest in Apicore, as well as an option to acquire remaining issued shares of Apicore until July 2017.  Full Article

Medicure exercises option to acquire majority interest in Apicore
Friday, 18 Nov 2016 07:30am EST 

Medicure Inc : Medicure inc- continues to have option rights until july 3, 2017 to acquire additional shares in Apicore . Medicure - allowing for acquisition of 4.7 million series a preferred shares, 1.3 million warrants for $33.3 million,bringing co's ownership in apicore to 64 percent .Medicure exercises option to acquire majority interest in Apicore.  Full Article

Medicure FDA approves new Aggrastat product format
Thursday, 1 Sep 2016 08:00am EDT 

Medicure Inc : FDA approves new AGGRASTAT® product format .Commercial release of bolus vial will take place at beginning of Q4 of this year.  Full Article

Medicure reports Q2 earnings per share $0.03
Wednesday, 10 Aug 2016 05:00pm EDT 

Medicure Inc : Medicure reports second quarter 2016 financial results . Qtrly earnings per share $0.03 .Says net revenue of $7.7 million during the quarter ended June 30, 2016, up 103 pct compared to $3.8 million last year.  Full Article

Medicure Inc qtrly earnings per share $0.01
Wednesday, 11 May 2016 06:27pm EDT 

Medicure Inc : Says recorded net revenue of $6.1 million during quarter ended March 31, 2016, an increase of 82% . Qtrly earnings per share $0.01 .Medicure reports first quarter 2016 financial results.  Full Article

Medicure says COO Dawson Reimer will leave the company
Monday, 9 May 2016 07:18pm EDT 

Medicure Inc : Employment agreement with president and chief operating officer, Dawson Reimer , has been terminated, effective immediately . Friesen, founder of Medicure, will, in addition to his current responsibilities, take on role of president of company .Medicure announces departure of president and chief operating officer.  Full Article

Medicure Inc announces ANDA collaboration with Apicore
Wednesday, 6 Jan 2016 08:00am EST 

Medicure Inc:Says has initiated development of a high-value cardiovascular generic drug.Project is a collaboration between Medicure International Inc and Apicore US LLC.Co and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights.Says companies anticipate filing the ANDA with U.S. food and drug administration by the end of 2016.  Full Article

Medicure Inc closes bought deal private placement financing for gross proceeds of $4,025,000
Friday, 26 Jun 2015 12:12pm EDT 

Medicure Inc:Closes its bought deal private placement financing with syndicate of underwriters led by PI Financial Corp. as Sole-Lead Underwriter and including Bloom Burton & Co.Says company issued 1,829,545 common shares of company at purchase price of $2.20 per Share.Gross proceeds was of about $4,025,000.Net proceeds of the offering will be used to fund product development costs related to AGGRASTAT, as well as for general corporate and working capital purposes.  Full Article

Medicure Inc announces $3.5 million "bought deal" private placement
Wednesday, 10 Jun 2015 04:01pm EDT 

Medicure Inc:Says underwriters have agreed to purchase, on a bought deal private placement basis, 1,590,909 common shares at a price of $2.20 per share for gross proceeds of $3,500,000.Net proceeds of the offering will be used to fund product development costs related to aggrastat.  Full Article

More From Around the Web

BRIEF-Medicure announces FDA approval for Apicore's generic tetrabenazine

* Medicure announces FDA approval for Apicore's generic tetrabenazine